OPTIMIZING LENTIVIRAL VECTOR PRODUCTION FOR CELL THERAPIES: ADVANCING MANUFACTURING STRATEGIES AT OMNIABIO

被引：0

作者：

Al Asafen, H. ^{[2
]}

Sudarsan, A. K. ^{[1
]}

Mcleod, A. ^{[2
]}

Kawka, K. ^{[2
]}

Maystrenko, A. ^{[2
]}

Sirskyj, D. ^{[2
]}

Bagheri, M. ^{[3
]}

Attignon, E. ^{[3
]}

Chettiar, D. ^{[1
]}

Beaudette, P. ^{[1
]}

Razvi, A. ^{[2
]}

Patel, N. ^{[1
]}

McNally, K. ^{[4
]}

Gacerez, A. ^{[4
]}

Fardy, M. ^{[4
]}

机构：

[1] Ctr Commercializat Regenerat Med, Toronto, ON, Canada

[2] Cytiva US, Marlborough, MA USA

[3] OmniaBio, Toronto, ON, Canada

[4] Chimera Bioengn, San Francisco, CA USA

来源：

CYTOTHERAPY | 2024年 / 26卷 / 06期

关键词：

lentivirus; bioreactor; process development;

D O I：

暂无

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

1143

引用

页码：E29 / E30

页数：2

共 50 条

[1] Slow and steady wins the race: Optimizing lentiviral vector production for efficient clinical-scale manufacturing
Mccarron, Alexandra
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 484 - 485
[2] ADVANCING LENTIVIRAL VECTOR MANUFACTURE FOR CLINICAL CELL AND GENE THERAPY
Michelet, F.
Szyniarowski, P.
Radhakrishnan, S.
Sin, W.
Leo, V. Ivon
Alagppan, D.
Lam, P.
Chan, L.
CYTOTHERAPY, 2021, 23 (05) : S174 - S175
[3] State of Producer Cell Development for Lentiviral Vector Manufacturing
Challener, Cynthia A.
BIOPHARM INTERNATIONAL, 2023, 36 (07)
[4] Lentiviral vector and suicide gene systems for T-cell therapies
Qasim, W
Chatziandreou, I
Thrasher, A
Gaspar, H
BONE MARROW TRANSPLANTATION, 2004, 33 : S22 - S22
[5] Cell line development for continuous lentiviral vector production
Tomas, H. A.
Rodrigues, A. F.
Mestre, D. A.
Alves, P. M.
Carrondo, M. J. T.
Coroadinha, A. S.
HUMAN GENE THERAPY, 2016, 27 (11) : A165 - A165
[6] DEVELOPING A SCALABLE, CHEMICALLY-DEFINED LENTIVIRAL VECTOR PRODUCTION PROCESS FOR GENE-MODIFIED CELL THERAPIES
Fiol, C. Ripoll
Collignon, M.
Welsh, J.
Rafiq, Q. A.
CYTOTHERAPY, 2023, 25 (06) : S268 - S268
[7] Accelerated development of producer cell lines for lentiviral vector production
Whiteley, E. S.
Boura, J. S.
Pearson, L. J. E.
Frost, L.
Todoric, R.
Hood, A.
Dunne, L.
Mitrophanous, K. A.
Stewart, H. J.
HUMAN GENE THERAPY, 2019, 30 (08) : A30 - A31
[8] FROM CENTRALIZED MANUFACTURING TO BEDSIDE PRODUCTION: ADVANCING CAR T-CELL THERAPIES THROUGH COLLABORATIVE INNOVATION
Desmet, T.
Simoens, S.
Van Dyck, W.
Huys, I
VALUE IN HEALTH, 2024, 27 (12) : S340 - S340
[9] Degradation of specific glycosaminoglycans improves transfection efficiency and vector production in transient lentiviral vector manufacturing processes
Williams-Fegredo, Thomas
Davies, Lee
Knevelman, Carol
Mitrophanous, Kyriacos
Miskin, James
Rafiq, Qasim A.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2024, 12
[10] Stable Producer Cell Lines for Production of Lentiviral Vectors for CAR T Cell Therapies
Beswick, Richard W.
Boura, Joana
Pemberton, Kirstie
Kapanidou, Maria
Todoric, Radmila
Wright, Jordan
Farley, Dan C.
Knevelman, Carol
Clarkson, Nicholas
Mitrophanous, Kyri
Davies, Lee
Stewart, Hannah J.
MOLECULAR THERAPY, 2023, 31 (04) : 460 - 460

← 1 2 3 4 5 →